Integrated Expression Profiling and ChIP-seq Analyses of the Growth Inhibition Response Program of the Androgen Receptor
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The androgen receptor (AR) plays important roles in the development of male phenotype and in different human diseases including prostate cancers. The AR can act either as a promoter or a tumor suppressor depending on cell types. The AR proliferative response program has been well studied, but its prohibitive response program has not yet been thoroughly studied. METHODOLOGY/PRINCIPAL FINDINGS: Previous studies found that PC3 cells expressing the wild-type AR inhibit growth and suppress invasion. We applied expression profiling to identify the response program of PC3 cells expressing the AR (PC3-AR) under different growth conditions (i.e. with or without androgens and at different concentration of androgens) and then applied the newly developed ChIP-seq technology to identify the AR binding regions in the PC3 cancer genome. A surprising finding was that the comparison of MOCK-transfected PC3 cells with AR-transfected cells identified 3,452 differentially expressed genes (two fold cutoff) even without the addition of androgens (i.e. in ethanol control), suggesting that a ligand independent activation or extremely low-level androgen activation of the AR. ChIP-Seq analysis revealed 6,629 AR binding regions in the cancer genome of PC3 cells with an FDR (false discovery rate) cut off of 0.05. About 22.4% (638 of 2,849) can be mapped to within 2 kb of the transcription start site (TSS). Three novel AR binding motifs were identified in the AR binding regions of PC3-AR cells, and two of them share a core consensus sequence CGAGCTCTTC, which together mapped to 27.3% of AR binding regions (1,808/6,629). In contrast, only about 2.9% (190/6,629) of AR binding sites contains the canonical AR matrix M00481, M00447 and M00962 (from the Transfac database), which is derived mostly from AR proliferative responsive genes in androgen dependent cells. In addition, we identified four top ranking co-occupancy transcription factors in the AR binding regions, which include TEF1 (Transcriptional enhancer factor), GATA (GATA transcription factors), OCT (octamer transcription factors) and PU1 (PU.1 transcription factor). CONCLUSIONS/SIGNIFICANCE: Our data provide a valuable data set in understanding the molecular basis for growth inhibition response program of the AR in prostate cancer cells, which can be exploited for developing novel prostate cancer therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays
Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., & Gilad, Y. (2008) · Genome Research · doi:10.1101/gr.079558.108 · Cited by 2,771
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 2×
“Alterations in AR sequences and expression levels and perturbations in AR signaling networks have significant roles in the genesis and maintenance of prostate cancers (PCa) [1–6].”
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 1×
“activation of the AR by other growth factors [7]; 2) mutations in the AR that change AR ligand specificity and allow AR to be activated by non-steroids or anti-androgens [8]; 3) over-expression of the AR [2,9–11]; 4) recruitment of new AR-cofactors [12].”
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., Euskirchen, G., Bernier, B., Varhol, R., Delaney, A., et al. (2007) · Nature Methods · doi:10.1038/nmeth1068 · Cited by 1,454 · cited 1×
“, the neuron-restrictive silencer factor (NRSF) and STAT1”
BackgroundA Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141 · cited 1×
“. Transcriptional factor (TF) binding sites can be localized to regions other than the 5′ proximal promoter regions, such as far upstream sequences, introns, and 3′ of the gene as exemplified by genome-wide localization analysis (GWLA) of two transcription factors (p53 and estrogen receptor)”
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · cited 1×
“Alterations in AR sequences and expression levels and perturbations in AR signaling networks have significant roles in the genesis and maintenance of prostate cancers (PCa) [1–6].”
Molecular regulation of androgen action in prostate cancer.
Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20794 · Cited by 336
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Massie, C. E., Adryan, B., Barbosa‐Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., & Mills, I. G. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401046 · Cited by 259
Direct, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element
Magee, J. A., Chang, L.-W., Stormo, G. D., & Milbrandt, J. (2006) · Endocrinology · doi:10.1210/en.2005-1001 · Cited by 174
Cited by
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
Androgen Receptor Structure, Function and Biology: From Bench to Bedside.
(2016) · Europe PMC (PubMed Central) · Cited by 623
Sahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A., Sankila, A., Turunen, J., Lundin, M., Konsti, J., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.328 · Cited by 390
Lawrence, M. G., Lai, J., & Clements, J. A. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0034 · Cited by 265
Metadata
- Authors
- Lin, B., Wang, J., Hong, X., Yan, X., Hwang, D., Cho, J.-H., Yi, D., Utleg, A. G., Fang, X., Schones, D. E., Zhao, K., Omenn, G. S., & Hood, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-08-11
- Volume
- 4
- Issue
- 8
- Pages
- e6589
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2083262188
- Cited by
- 81
- References
- 10
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated Expression Profiling and ChIP-seq Analyses of the Growth Inhibition Response Program of the Androgen Receptor. https://app.cochat.ai/papers/10.1371/journal.pone.0006589
- The paper
- Lin, B., Wang, J., Hong, X., Yan, X., Hwang, D., Cho, J.-H., Yi, D., Utleg, A. G., Fang, X., Schones, D. E., Zhao, K., Omenn, G. S., & Hood, L. (2009). Integrated Expression Profiling and ChIP-seq Analyses of the Growth Inhibition Response Program of the Androgen Receptor. PLoS ONE. https://doi.org/10.1371/journal.pone.0006589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.